SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published articles

17 Jan 2013 07:00

RNS Number : 7246V
Tristel PLC
17 January 2013
 



Tristel plc

("Tristel")

 

Peer-reviewed published articles supporting Tristel's technology and products

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of two articles in peer-reviewed journals that describe the benefits of Tristel products.

 

The first is titled "Guidelines for Reprocessing Non-lumened Heat-Sensitive Ear/Nose/Throat Endoscopes" and has been published in The Laryngoscope, the journal of The American Laryngological, Rhinological and Otological Society (Laryngoscope , 122:1708-1718, 2012). The article proposes the standardisation of disinfection procedures for ENT endoscopes and reviews a number of technologies including Tristel's Wipes System, Stella decontamination system and Shine automated washer-disinfector. 

 

The second publication is of a study undertaken in the Prince of Wales Hospital, Hong Kong, and is titled "Transvaginal ultrasound probe contamination by the human papillomavirus in the emergency department" (Emergency Medicine Journal, July 2012). The study revealed the prevalence of human papillomavirus (HPV) on the ultrasound equipment used routinely in the hospital and indicated that existing disinfection methods were inappropriate. The hospital has adopted the Tristel Wipes System to improve its decontamination process. 

 

Tristel CEO, Paul Swinney, commented: "We believe the Wipes System is now gaining recognition as the "gold standard" for ENT endoscopes in countries where it has been approved for use, which include all those in the European Community, Australia and many countries in the Far East. Whilst we have not attempted to register the Wipes System in the United States, its inclusion in The Laryngoscope review of decontamination methodologies, which is the most widely read journal for ENT worldwide, is a significant benefit to the marketing of our product.

 

"A second area in the hospital where the Wipes System is achieving rapid uptake in the United Kingdom and Australia is ultrasound. The Prince of Wales study joins a growing body of scientific evidence that existing methods of disinfecting intra-vaginal and rectal ultrasound probes are inadequate. The Wipes System is considered to be a more effective method of disinfection. In terms of patient procedures, and therefore disinfectant use, ultrasound is as large a market as digestive and respiratory medicine where almost all the attention of the infection control market has been focused for the past twenty years. Our product strategy of focusing on the smaller non-lumened instruments used in ENT and ultrasound positions us well for continued growth in this area."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFUFMMFDSEDF
Date   Source Headline
10th Jun 20267:00 amRNSExercise of Share Options & Total Voting Rights
13th May 202610:10 amRNSExercise of Share Options and Total Voting Rights
5th May 20267:00 amRNSExercise of Share Options and Total Voting Rights
20th Apr 20262:28 pmRNSHolding(s) in Company
20th Apr 20268:20 amRNSHolding(s) in Company
23rd Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNS-RConference attendance at ShareSoc Leeds
17th Mar 20265:13 pmRNSHolding(s) in Company
3rd Mar 20264:04 pmRNSPCA Dealing
2nd Mar 20267:00 amRNSHalf-year Financial Report
12th Feb 20267:00 amRNSExercise of Share Options and Total Voting Rights
6th Feb 202611:56 amRNSExercise of Share Options and Total Voting Rights
6th Feb 20267:00 amRNSNotice of Results
22nd Jan 20267:00 amRNSPositive H1 Trading Update & Directorate Change
8th Jan 20263:10 pmRNSExercise of Share Options and Total Voting Rights
12th Dec 202510:37 amRNSDirector/PDMR Shareholding
12th Dec 20259:19 amRNSExercise of Share Options and Total Voting Rights
11th Dec 202511:54 amRNSResult of AGM
11th Dec 20257:00 amRNSAGM Statement
24th Nov 202512:28 pmRNSDirector Option Grant
24th Nov 20257:00 amRNSUpdated US guidelines for high level disinfection
18th Nov 20257:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
12th Nov 202511:33 amRNSHolding(s) in Company
31st Oct 20254:11 pmRNSHolding(s) in Company
31st Oct 20252:12 pmRNSHolding(s) in Company
22nd Oct 20254:56 pmRNSHolding(s) in Company
16th Oct 20254:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 202512:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 20257:00 amRNSFinal Results
9th Oct 202510:06 amRNSExercise of Share Options and Total Voting Rights
25th Sep 20257:00 amRNSVISICLEAN Product Launch
16th Sep 20257:00 amRNSNotice of Preliminary Results
11th Sep 20257:00 amRNSExercise of Share Options and Total Voting Rights
1st Sep 20257:00 amRNSConfirmation of CFO Appointment
21st Aug 20253:56 pmRNSHolding(s) in Company
18th Aug 202512:15 pmRNSExercise of Share Options and Total Voting Rights
6th Aug 20254:05 pmRNS-RCapital Markets Day video update
29th Jul 20257:00 amRNSTrading update
24th Jul 20257:00 amRNSConfirmation of Investor presentations
17th Jul 20257:00 amRNSAppointment of Chief Financial Officer
4th Jul 20251:02 pmRNSHolding(s) in Company
26th Jun 20257:00 amRNS-RAPIC25 Annual Conference attendance
2nd Jun 20257:00 amRNSInvestor Presentations & Notice of Trading Update
30th May 20257:00 amRNSHolding(s) in Company
28th May 20257:00 amRNS-RConference attendance at Mello2025 Investor event
16th May 20257:00 amRNSExercise of Share Options and Total Voting Rights
15th May 20257:00 amRNSCFO succession planning
12th May 20257:00 amRNSFDA clearance for Tristel OPH
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.